Javascript must be enabled to continue!
Mucormycosis in a Patient with Chronic Lymphatic Leukemia in Treatment with Ibrutinib
View through CrossRef
Invasive Fungal Infection (IFI) is a serious complication in patients with hematologic malignancies. We present a case of invasive Mucormycosis in a patient with Chronic Lymphatic Leukemia (CLL). This case of Mucormycosis illustrates invasive fungal infections as a complication to chronic hematologic diseases and adds to other publications that suggest a relationship with novel treatments of CLL such as ibrutinib. Treatment of the IFI was successful without having to stop ibrutinib. We present relevant publications and discuss clinical controversies that arise.
Title: Mucormycosis in a Patient with Chronic Lymphatic Leukemia in Treatment with Ibrutinib
Description:
Invasive Fungal Infection (IFI) is a serious complication in patients with hematologic malignancies.
We present a case of invasive Mucormycosis in a patient with Chronic Lymphatic Leukemia (CLL).
This case of Mucormycosis illustrates invasive fungal infections as a complication to chronic hematologic diseases and adds to other publications that suggest a relationship with novel treatments of CLL such as ibrutinib.
Treatment of the IFI was successful without having to stop ibrutinib.
We present relevant publications and discuss clinical controversies that arise.
Related Results
Unusual Presentation of Mixed Lymphatic Malformation: A Case Report with Literature Review
Unusual Presentation of Mixed Lymphatic Malformation: A Case Report with Literature Review
Abstract
Introduction
There is a scarcity of reports on mixed lymphatic malformation. This case highlights a child with an extensive mixed lymphatic malformation, disfiguring multi...
Developing Novel Therapeutic Strategies to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
Developing Novel Therapeutic Strategies to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
Abstract
MCL accounts for 7% of all non-Hodgkin lymphoma cases and is a rare and incurable subtype of B-cell lymphoma. Unfortunately, most MCL patients experience di...
Genetically Defined Metabolic Targets Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
Genetically Defined Metabolic Targets Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
Background: Mantle cell lymphoma (MCL), which accounts for around 7% of non-Hodgkin lymphomas, is currently incurable. MCL's key survival pathway is the B-cell receptor pathway, an...
Abstract 4391: Overcoming primary ibrutinib resistance in mantle cell lymphoma
Abstract 4391: Overcoming primary ibrutinib resistance in mantle cell lymphoma
Abstract
Mantle cell lymphoma (MCL) is a rare and incurable subtype of B-cell lymphoma. In a phase II study of ibrutinib in MCL patients, most of the patients respon...
Simultaneous Inhibition of BCL-2 and PI3K Signaling Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
Simultaneous Inhibition of BCL-2 and PI3K Signaling Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma
Abstract
Background:
Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy that is initially responsive but ultimately relapses to frontline t...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
PB1900 IBRUTINIB: INCREASED SUSCEPTIBILITY TO INFECTIONS AND USE OF RESOURCES ASSOCIATED
PB1900 IBRUTINIB: INCREASED SUSCEPTIBILITY TO INFECTIONS AND USE OF RESOURCES ASSOCIATED
Background:Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK), a signaling molecule which is involved in the maturation of B‐cells. BTK is essential in the si...

